RELA
1 product
10 abstracts
Abstract
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.Org: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, University Hospital Zurich, Zürich, Switzerland, CEPCM, Dermatology and Skin Cancer Department, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France, Linear Clinical Research, Nedlands, Western Australia, Australia, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.Org: Instituto Oncológico Fundación Arturo López Pérez and Department of Oncology, Instituto Nacional del Cáncer, Santiago, Chile, FAICIC Clinical Research, Veracruz, Mexico, Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France,
Abstract
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.Org: Alaska Oncology and Hematology, LLC., Bristol Myers Squibb Research,
Abstract
Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).Org: Department of Immunology, University of Pittsburgh,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).Org: Analysis Group Ltd.,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).Org: Melanoma Institute Australia,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.Org: University of Texas MD Anderson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University Duisburg-Essen, German Cancer Consortium, Instituto Oncológico Fundación Arturo López Pérez,
Abstract
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas - M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.Org: Melanoma Institute Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, Chris O'Brien Lifehouse, The University of Sydney, The Mater Hospital Sydney,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).Org: University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Partner Site Munich, Partner Site Essen,
Product
relatlimab+nivolumab